SG11201502973YA - Injectable cancer compositions - Google Patents

Injectable cancer compositions

Info

Publication number
SG11201502973YA
SG11201502973YA SG11201502973YA SG11201502973YA SG11201502973YA SG 11201502973Y A SG11201502973Y A SG 11201502973YA SG 11201502973Y A SG11201502973Y A SG 11201502973YA SG 11201502973Y A SG11201502973Y A SG 11201502973YA SG 11201502973Y A SG11201502973Y A SG 11201502973YA
Authority
SG
Singapore
Prior art keywords
cancer compositions
injectable
injectable cancer
compositions
cancer
Prior art date
Application number
SG11201502973YA
Inventor
Andrew X Chen
Yali Tsai
Original Assignee
Genspera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genspera Inc filed Critical Genspera Inc
Publication of SG11201502973YA publication Critical patent/SG11201502973YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
SG11201502973YA 2012-10-16 2013-10-14 Injectable cancer compositions SG11201502973YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261714662P 2012-10-16 2012-10-16
PCT/US2013/064889 WO2014062587A2 (en) 2012-10-16 2013-10-14 Injectable cancer compositions

Publications (1)

Publication Number Publication Date
SG11201502973YA true SG11201502973YA (en) 2015-05-28

Family

ID=50488875

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502973YA SG11201502973YA (en) 2012-10-16 2013-10-14 Injectable cancer compositions

Country Status (16)

Country Link
US (1) US20150265572A1 (en)
EP (1) EP2908838A4 (en)
JP (1) JP2015534951A (en)
KR (1) KR20150092109A (en)
CN (1) CN104870006A (en)
AU (1) AU2013331518A1 (en)
BR (1) BR112015008421A2 (en)
CA (1) CA2888141A1 (en)
CL (1) CL2015000923A1 (en)
EA (1) EA201590521A1 (en)
HK (1) HK1211203A1 (en)
IL (1) IL238358A0 (en)
MX (1) MX2015004703A (en)
SG (1) SG11201502973YA (en)
WO (1) WO2014062587A2 (en)
ZA (1) ZA201502533B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
PL3154594T3 (en) 2014-06-13 2023-10-09 Bach Biosciences, Llc Fap-activated therapeutic agents, and uses related thereto
FR3031678B1 (en) * 2015-01-19 2019-07-26 Universite Des Sciences Et Technologies De Lille JOINT USE OF ASP-8ADT AND AN AUTOPHAGIA INHIBITOR IN THE TREATMENT OF CANCER.
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055052A1 (en) * 2000-11-10 2003-03-20 Stefan Peters FAP-activated anti-tumor compounds
WO2002043773A2 (en) * 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EP1986634A2 (en) * 2005-10-12 2008-11-05 Trojanon GmbH & Co. KG Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
US7635682B2 (en) * 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
BRPI0916535A2 (en) * 2008-07-23 2015-11-10 Bharat Serums & Vaccines Ltd docetaxel nanoemulsion of oil in stable injectable water.
WO2010107909A2 (en) * 2009-03-17 2010-09-23 The Johns Hopkins University Methods and compositions for the detection of cancer
WO2011153513A2 (en) * 2010-06-03 2011-12-08 Latitude Pharma Nanoemulsion composition containing vitamin k

Also Published As

Publication number Publication date
AU2013331518A1 (en) 2015-04-30
CL2015000923A1 (en) 2015-08-07
WO2014062587A2 (en) 2014-04-24
KR20150092109A (en) 2015-08-12
US20150265572A1 (en) 2015-09-24
EP2908838A2 (en) 2015-08-26
CN104870006A (en) 2015-08-26
IL238358A0 (en) 2015-06-30
JP2015534951A (en) 2015-12-07
WO2014062587A3 (en) 2014-07-17
MX2015004703A (en) 2015-10-12
HK1211203A1 (en) 2016-05-20
CA2888141A1 (en) 2014-04-24
BR112015008421A2 (en) 2017-08-08
EA201590521A1 (en) 2015-09-30
EP2908838A4 (en) 2016-12-21
ZA201502533B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
HK1257028A1 (en) Injectable preparation
HK1215165A1 (en) Compositions
HK1210019A1 (en) Chitosan-derived compositions
HK1204551A1 (en) Injectable compositions
HK1208354A1 (en) Compositions
HK1211203A1 (en) Injectable cancer compositions
ZA201503157B (en) Compositions
GB201210800D0 (en) Compositions
GB201209244D0 (en) Compositions
GB201201287D0 (en) Compositions
ZA201503062B (en) Compositions
GB201220068D0 (en) Compositions
ZA201502542B (en) Compositions
GB201219980D0 (en) Compositions
GB201219962D0 (en) Compositions
GB201219973D0 (en) Compositions
ZA201504227B (en) Phenylpyrazole injectable compositions
TWI561248B (en) Peracid-generating compositions
EP2926813A4 (en) Metformin-orlistat compositions
GB201223148D0 (en) Compositions
GB201222702D0 (en) Compositions
GB201218959D0 (en) Compositions
GB201209189D0 (en) Compositions
GB201209187D0 (en) Compositions
GB201204103D0 (en) Compositions